We can’t show the full text here under this license. Use the link below to read it at the source.
Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
Once-weekly dulaglutide effects vary with initial insulin-producing cell function in type 2 diabetes
AI simplified
Abstract
Patients with low baseline beta-cell function experienced a 1.55% reduction in HbA1c after 26 weeks of dulaglutide treatment.
- Patients with lower beta-cell function had higher levels of glycated hemoglobin (HbA1c) and longer duration of diabetes.
- The low beta-cell function tertile exhibited greater reductions in HbA1c compared to the high tertile after 26 weeks of treatment.
- Adjusting for baseline HbA1c eliminated differences in HbA1c reduction between beta-cell function tertiles.
- Greater decreases in fasting blood glucose and greater increases in fasting C-peptide were noted in the low beta-cell function tertile.
- All tertiles showed similar increases in beta-cell function as measured by .
AI simplified
Key numbers
-1.55%
HbA1c Reduction in Low Tertile
Change in HbA1c at 26 weeks for low beta-cell function tertile
-0.98%
HbA1c Reduction in High Tertile
Change in HbA1c at 26 weeks for high beta-cell function tertile
1346 patients
Overall Patient Cohort
Total number of patients treated with dulaglutide in the analysis